A prospective randomized controlled clinical trial investigating the efficacy of low-dose olanzapine in preventing nausea and vomiting associated with oxaliplatin-based and irinotecan-based chemotherapy

HIGHLIGHTS

• What: The aim of this study is to assess the clinical efficacy of a 5 mg dosage of olanzapine in preventing chemotherapyinduced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) among female patients diagnosed with gastrointestinal tract tumors. Efficacy assessment During the 0-120 h post-chemotherapy, the study aimed to document the frequency, duration, and severity of daily occurrences of nausea and vomiting. This study demonstrated a heightened antiemetic efficacy of aprepitant when combined with palonosetron and dexamethasone within the context of FOLFOX or FOLFIRI chemotherapy regimens (Wang et_al 2021). This trial demonstrated that . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.